125 related articles for article (PubMed ID: 38760615)
1. An observational study on the safety of teprotumumab based on FAERS database.
Wang XL; Xu SS; Zhou JB; Song ZH
Endocrine; 2024 May; ():. PubMed ID: 38760615
[TBL] [Abstract][Full Text] [Related]
2. Data mining and analysis of adverse event signals associated with teprotumumab using the Food and Drug Administration adverse event reporting system database.
Zhang S; Wang Y; Qi Z; Tong S; Zhu D
Int J Clin Pharm; 2024 Apr; 46(2):471-479. PubMed ID: 38245664
[TBL] [Abstract][Full Text] [Related]
3. Post-marketing Safety Concerns of Teprotumumab: A Real-World Pharmacovigilance Assessment.
Huang J; Su A; Yang J; Zhuang W; Li Z
J Clin Endocrinol Metab; 2024 Jun; ():. PubMed ID: 38878281
[TBL] [Abstract][Full Text] [Related]
4. Disproportionality analysis of quinolone safety in children using data from the FDA adverse event reporting system (FAERS).
Kong W; Mao W; Zhang L; Wu Y
Front Pediatr; 2022; 10():1069504. PubMed ID: 36714649
[TBL] [Abstract][Full Text] [Related]
5. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib.
Yin Y; Shu Y; Zhu J; Li F; Li J
Sci Rep; 2022 Nov; 12(1):19555. PubMed ID: 36380085
[TBL] [Abstract][Full Text] [Related]
6. Post-marketing safety of immunomodulatory drugs in multiple myeloma: A pharmacovigilance investigation based on the FDA adverse event reporting system.
Jiang T; Su H; Li Y; Wu Y; Ming Y; Li C; Fu R; Feng L; Li Z; Li L; Ni R; Liu Y
Front Pharmacol; 2022; 13():989032. PubMed ID: 36532784
[No Abstract] [Full Text] [Related]
7. A real-world disproportionality analysis of apalutamide: data mining of the FDA adverse event reporting system.
Fang Z; Xu Z; Zhu W; Yu M; Ji C
Front Pharmacol; 2023; 14():1101861. PubMed ID: 37342589
[No Abstract] [Full Text] [Related]
8. Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database.
Liu W; Du Q; Guo Z; Ye X; Liu J
Front Pharmacol; 2023; 14():1283247. PubMed ID: 38027003
[No Abstract] [Full Text] [Related]
9. A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS).
Zou SP; Yang HY; Ouyang ML; Cheng Q; Shi X; Sun MH
BMC Pharmacol Toxicol; 2023 Nov; 24(1):62. PubMed ID: 37957717
[TBL] [Abstract][Full Text] [Related]
10. Real-world safety of Levetiracetam: Mining and analysis of its adverse drug reactions based on FAERS database.
He Z; Liu C; Lin L; Feng G; Wu G
Seizure; 2024 Apr; 117():253-260. PubMed ID: 38537425
[TBL] [Abstract][Full Text] [Related]
11. Adverse event profiles of PCSK9 inhibitors alirocumab and evolocumab: Data mining of the FDA adverse event reporting system.
Ji C; Bai J; Zhou J; Zou Y; Yu M
Br J Clin Pharmacol; 2022 Dec; 88(12):5317-5325. PubMed ID: 35818959
[TBL] [Abstract][Full Text] [Related]
12. Post-marketing safety evaluation of lurbinectedin: a pharmacovigilance analysis based on the FAERS database.
Li Z; Guo C; Liu X; Qiu Z; Zhang R
Front Pharmacol; 2024; 15():1368763. PubMed ID: 38549677
[No Abstract] [Full Text] [Related]
13. Real-world safety of Lacosamide: A pharmacovigilance study based on spontaneous reports in the FDA adverse event reporting system.
Liu P; He M; Xu X; He Y; Yao W; Liu B
Seizure; 2023 Aug; 110():203-211. PubMed ID: 37423166
[TBL] [Abstract][Full Text] [Related]
14. Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system.
Xiong R; Lei J; Pan S; Zhang H; Tong Y; Wu W; Huang Y; Lai X
Front Pharmacol; 2023; 14():1226086. PubMed ID: 37781705
[No Abstract] [Full Text] [Related]
15. Safety of triazole antifungals: a pharmacovigilance study from 2004 to 2021 based on FAERS.
Chai S; Zhan JL; Zhao LM; Liu XD
Ther Adv Drug Saf; 2022; 13():20420986221143266. PubMed ID: 36545565
[TBL] [Abstract][Full Text] [Related]
16. [Study on mining of signals of adverse drug reactions of entecavir and tenofovir disoproxil based on the US FAERS database].
Liu X; Chen L; Zhao L
Zhonghua Gan Zang Bing Za Zhi; 2021 Sep; 29(9):830-836. PubMed ID: 34638200
[No Abstract] [Full Text] [Related]
17. Drug-induced interstitial lung disease: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System from 2004 to 2021.
Jiang T; Su H; Xu J; Li C; Zhang N; Li Y; Wu Y; Ni R; Ming Y; Li Z; Li L; Liu Y
Ther Adv Drug Saf; 2024; 15():20420986231224227. PubMed ID: 38293566
[TBL] [Abstract][Full Text] [Related]
18. Safety of daratumumab in the real-world: a pharmacovigilance study based on FAERS database.
Wu J; Wu H; Chen L; Liang H; Huang G; Yang S; Chen B; Noguchi Y; Shen Y
Expert Opin Drug Saf; 2023 Dec; ():1-12. PubMed ID: 38108285
[TBL] [Abstract][Full Text] [Related]
19. Adverse event reporting of four anti-Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system.
Sun W; Li Y; Xia B; Chen J; Liu Y; Pang J; Liu F; Cheng H
Front Pharmacol; 2023; 14():1257282. PubMed ID: 38264523
[No Abstract] [Full Text] [Related]
20. Adverse events associated with brolucizumab: a disproportionality analysis of the FDA adverse event reporting system (FAERS).
Xiong X; Zhang X; Li X; Huang T
Expert Opin Drug Saf; 2024 Feb; ():1-6. PubMed ID: 38404234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
